Abstract:67 Background: Previous studies indicate a preexisting T cell response and the associated “adaptive immune resistance” are critical for the clinical efficacy of anti-PD-1/PD-L1 immunotherapy. The study explored the activated IFN-γ pathway and the expression of interferon regulatory factor 1 (IRF-1), as surrogates of preexisting T cell response, as potential biomarkers associated with clinical benefit (CB) for ESCC patients receiving anti-PD-1/PD-L1 therapy. Methods: Thirty-one ESCC patients treated with PD-1/PD-L1 blockade antibody, alone or in combination, were enrolled. Tumor response evaluation was made according to Response Evaluation Criteria in Solid Tumours 1.1, and CB was defined as complete response, partial response or stable disease at least 6 months. Formalin-fixed paraffin-embedded tissues from 31 patients were analyzed for the expression of PD-L1 and IRF-1 by immunohistochemistry; 13 tissues were analyzed for the expression of immune-related genes by NanoString nCounter Human PanCancer Immune Profiling. Results: Of 31 enrolled patients (M: F= 30: 1, median age of 58), 23 and 8 were of recurrent and de novo metastatic ESCC. Sixteen and 15 received PD-1/PD-L1 blockade alone and PD-1/PD-L1-based combination therapy, respectively; 13 had received at least 2 lines of systemic therapy for advanced disease. The response rate was 10%, and the CB rate was 16%. The median progression-free-survival (PFS) and overall survival are 1.8 and 5.6 months, respectively. The 25-gene IFN-γ signature was significant higher in patients with CB than in patients without CB ( P = 0.020). Neither PD-L1 expression on tumor cells (TC) nor on immune cells (IC) was associated with CB ( P = 0.489 and 0.646, respectively). However, the IRF-1 expression on TC or on IC was significantly associated with CB ( P < 0.001 and 0.005, respectively). Conclusions: Activated IFN-γ pathway determined by 25-gene IFN-γ signature and high IHC-expression of IRF-1 were associated with CB in advanced ESCC patients receiving anti-PD-1/PD-L1-based therapy. (Supported by the grant of MOST 105-2314-B-002 -186 -MY3).

The expression and clinical significance of IRF2 in esophageal squamous cell carcinoma

Involvement of IFN Regulatory Factor (IRF)-1 and IRF-2 in the Formation and Progression of Human Esophageal Cancers

Association between tumor necrosis factor receptor 2 and progression and poor prognosis of tumor stage 2‐3 esophageal squamous cell carcinoma and stratified analysis

Activated Interferon-Γ (Ifn-Γ) Pathway Associated with Clinical Benefit to Programmed Cell Death Protein-1 (PD-1)/PD Ligand 1 (Pd-L1)-based Therapy in Esophageal Squamous Cell Carcinoma (ESCC).

Prognostic Value of IRF-2 Expression in Colorectal Cancer.

The relationship between the expression and clinical significance of Nrf2 and Bcl-2 in esophageal squamous cell carcinoma

Clinical Significance of the Expression of EGFR Signaling Pathway-Related Proteins in Esophageal Squamous Cell Carcinoma

Expression and functional analyses of TERF2 in esophageal carcinoma

Defective expression of C20orf54 in esophageal dysplasia: a possible biomarker of esophageal carcinoma for early detection

Up-regulation of EIF3e is Associated with the Progression of Esophageal Squamous Cell Carcinoma and Poor Prognosis in Patients.

Data from Negative Feedback Regulation of IFN-γ Pathway by IFN Regulatory Factor 2 in Esophageal Cancers

The Finite Model Property for the Implicational Fragment of IPC Without Exchange and Contraction

Negative Feedback Regulation of IFN-γ Pathway by IFN Regulatory Factor 2 in Esophageal Cancers

Clinical significance of signal regulatory protein alpha (SIRPα) expression in esophageal squamous cell carcinoma

Interferon Regulatory Factor (IRF)-1 and IRF-2 Are Associated with Prognosis and Tumor Invasion in HCC

The IRF family can influence tumor immunity and the prognosis of patients with colorectal cancer

[Expression and Clinical Significance of BRCA1 in Human Esophageal Squamous Cell Carcinoma].

Expression of VEGF-C correlates with a poor prognosis based on analysis of prognostic factors in 73 patients with esophageal squamous cell carcinomas.

Clinical significance and biological function of interferon regulatory factor 1 in non-small cell lung cancer

Negative Feedback Regulation Of Ifn-Gamma Pathway By Ifn Regulatory Factor 2 In Esophageal Cancers

Expressions of Oct4 and Sox2 Protein and Their Correlations in Esophageal Squamous Cell Carcinoma